Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis

BARCELONA, Spain--(BUSINESS WIRE)--Oct 11, 2023--

Related Keywords

Germany ,Netherlands ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Austria ,Berlin ,France ,United Kingdom ,Switzerland ,Italy ,Belgium ,Spanish ,German ,Ulrich Mrowietz ,Matthias Augustin ,Omar Ram ,Volker Koscielny ,World Health Organization Wellbeing Index ,Venereology Congress ,Founder Of The Psoriasis Center ,European Academy Of Dermatology ,Corporate Communications ,European Association Of Dermatology ,Spanish Stock Exchange ,University Medical Center Schleswig Holstein ,European Association ,Psoriasis Center ,University Medical Center ,Chief Medical Officer ,Noble Purpose ,European Academy ,Safe Treatment ,Psoriatic Disease ,Real World Prospective Cohort Study ,Business Wire ,Region ,